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Combination of a third generation bisphosphonate and 
replication-competent adenoviruses produces synergistic cytotoxicity 
on mesothelioma 
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Abstract 
Background: Approximately 80% of mesothelioma specimens have the wild-type p53 gene, 
whereas they contain homozygous deletions in the INK4A/ARF locus that encodes p14ARF and 
the 16INK4A. We examined whether zoledronic acid (ZOL), a third generation bisphosphonate, 
and adenoviruses with a deletion of the E1B-55kD gene (Ad-delE1B55), which augments p53 
levels in the infected tumors, could produce possible combinatory anti-tumor effects on human 
mesothelioma cells bearing the wild-type p53 gene. 
Methods: Cytotoxicity of ZOL and Ad-delE1B55 was assessed with a WST assay. Cell cycle 
changes were tested with flow cytometry. Expression levels of relevant molecules were 
examined with western blot analysis to analyze a possible combinatory mechanism. 
Furthermore, the expressions of Ad receptors on target cells and infectivity were investigated 
with flow cytometry. Viral replications were examined with the tissue culture infection dose 
method. 
Results: Synergistic cytotoxic effects were produced by ZOL and Ad-delE1B55 on 
mesothelioma. Sub-G1 and S-phase populations increased compared with a single treatment of 
ZOL or Ad-delE1B55. The combinatory treatment induced p53 phosphorylation and 
subsequently enhanced the cleavage of caspase-3, 8, 9 and poly (ADP-ribose) polymerase, but 
did not influence expression of molecules involved in autophagy pathways. The Ad infectivity 
and replication of Ad-delE1B55 was stronger in the combination than those without ZOL 
treatment although the expression levels of Ad receptors remained unchanged. 
Conclusions: These findings indicated that combination of ZOL and Ad-delE1B55 induce 
synergistic anti-tumor effects through apoptotic pathways. 
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Introduction 
 Malignant pleural mesothelioma, developed in the pleural cavity, is highly related to 
exposure to asbestos in the patient history [1,2]. Approximately 80% of mesothelioma showed 
homozygous deletions in the INK4A/ARF locus which encodes p14ARF and the 16INK4A but the 
p53 was infrequently mutated [3,4]. The prognosis remains poor despite recent therapeutic 
modalities, and a novel therapeutic strategy is required to improve the survival. 
 Bisphosphonates (BPs) are synthetic analogues of pyrophosphates and strongly show 
affinity for mineralized bone matrix [5]. Recent reports showed that BPs had cytotoxic activities 
on tumors such as breast and prostate cancer [6,7], and these cytotoxic actions were attributable 
to a number of mechanisms including apoptosis induction and anti-angiogenesis [8, 9]. 
Zoledronic acid (ZOL), one of the third generation BPs, inhibits the farnesyl pyrophosphate 
synthetase, a key enzyme in the mevalonate pathway, and depletes isoprenoid pools, which 
subsequently results in decreased prenylation of small guanine-nucleotide-binding regulatory 
proteins (small G proteins). Consequently, ZOL prevented growth, adhesion or spreading, and 
invasion of cancer cells [5,10]. In our previous study, we investigated ZOL-mediated cytotoxic 
effects on mesothelioma cells [11]. Furthermore, ZOL treatments improved cytotoxicity of 
adenoviruses (Ad) expressing the p53 gene on mesothelioma, showing that ZOL-mediated 
augmentation of p53 was essential in the combinatory effects with a p53 up-regulating agent 
[12]. 
 Replicating Ad is a new strategy for cancer therapy. They can spread and destroy tumors 
without deleterious effects in normal tissues [13]. Replication-competent Ad continuously 
release the progenies from infected tumors and consequently circumvent low transduction 
efficacy. This replicable propensity enhances the cytotoxicity although host immunity is 
inhibitory to the viral spreading. Ad lacking the E1B-55kDa molecules (Ad-delE1B55) are 
replication-competent and were originally hypothesized to target only p53-mutated or -null 
tumors due to the defect in p53-inactivating E1B-55 kDa protein [14]. However, Ad proteins 
synthesized during the replications regulate p53 expression at various levels even in an 
epigenetic manner [15]. Ad-delE1B55-induced cytotoxicity was related to accumulation of p53 
phosphorylation. Additionally, our previous study showed that Ad-delE1B55 produced 
cytotoxicity on mesothelioma cells in a combination with the first- line chemotherapeutic agents 
[16]. 
 In the present study, we examined whether ZOL and Ad-delE1B55 could produce 
combinatory anti-tumor effects on human mesothelioma cells carrying the wild-type p53 gene. 
Furthermore, we indicated that combinatory effects were induced through apoptotic pathways. 
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Material and methods 
Cells 
 Human mesothelioma cells, MSTO-211H, NCI-H28 and NCI-H226, which were purchased 
from American Type Culture Collection (Manassas, VA, USA), were cultured with RPMI 1640 
medium with 10% fetal calf serum. HEK 293 and A549 cells (provided from Dr. Katsutyuki 
Hamada, Ehime University, Japan) were cultured with in Dulbecco’s Modified Eagle’s Medium 
containing 10% fetal calf serum. 
 
Ad preparation 
 Replication-competent Ad-delE1B55, in which the 55kDa molecule-encoding E1B region 
is deleted, and replication-incompetent Ad expressing the ß-galactosidase (Ad-LacZ) or the 
green fluorescent protein gene (Ad-GFP) powered by the cytomegalovirus promoter, were 
prepared with an Adeno-X expression system (Takara, Shiga, Japan) and HEK293 cells. The 
numbers of virus particles (vp) per ml was estimated with the formula [absorbance at 260 nm of 
purified Ad in the presence of 0.1 % sodium dodecyl sulfate. 
 
Cell cycle analysis 
 Cells were fixed in ice-cold 100% ethanol, incubated with RNase (50 µg/ml) and stained 
with propidium iodide (50 µg/ml). The staining profiles were analyzed with FACSCalibur and 
CellQuest software (BD Biosciences, CA, USA). 
 
Viability test in vitro 
 Cells (5 x 103/well) seeded in 96-well plates cultured with ZOL (Novartis, Basel, 
Switzerland), Ad-delE1B55 or ZOL plus Ad-delE1B55 for 5 days. Cell viability was determined 
with a cell-counting WST kit (Wako, Osaka, Japan) and the relative viability was calculated 
based on the absorbance without any treatments. Viable cell numbers were also counted with the 
trypan blue dye exclusion test. Combinatory effects were examined with CalcuSyn software 
(Biosoft, Cambridge, UK). Combination index (CI) values at respective fractions affected (Fa) 
points, which showed relative suppression levels of cell viability, were calculated based on the 
WST assay. CI < 1, CI = 1 and CI > 1 indicate synergistic, additive and antagonistic actions, 
respectively. 
 
Western blot analysis 
 Cells were cultured with ZOL and/or Ad and the cell lysate was subjected to sodium dodecyl 
sulfate polyacrylamide gel electrophoresis. The protein was transferred to a nylon filter and was 
hybridized with antibodies (Ab), against p53 (Thermo Fisher Scientific, Fremont, CA, USA), 
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phosphorylated p53 at serine (Ser) 15, Bid, caspase-3, cleaved caspase-3, caspase-8, cleaved 
caspase-8, caspase-9, cleaved caspase-9, poly (ADP-ribose) polymerase (PARP), Beclin-1, Atg5, 
LC3A/B (Cell Signaling, Danvers, MA, USA), type 2/5 Ad E1A (Santa Cruz Biotech, Dallas, 
TX, USA), phosphorylated H2AX at Ser 139 (Biolegend, San Diego, CA, USA), and α-tubulin 
(Thermo Fisher Scientific) as a control. The membranes were developed with the ECL system 
(GE Healthcare, Buckinghamshire, UK). 
 
Infectivity with Ad-GFP and expression of Ad receptors 
 Cells were infected with Ad-GFP at a certain vp dose for 30 min and were then washed to 
remove Ad. Infected cells were cultured for 2 days and then analyzed for percentages of 
GFP-positive cells with FACSCalibur (BD Biosciences) and CellQuest software (BD 
Biosciences). Cells of which fluorescence was greater than the brightest 5% of uninfected cells 
were judged as positively stained. For detecting Ad receptors, cells were stained with 
anti-coxsackie adenovirus receptors (CAR) (Upstate, Charlottesville, VA, USA), integrin αvβ3 
(Chemicon, Billerica, MA, USA), integrin αvβ5 (Abcam, Cambrige, UK) and the fluorescence 
intensity was analyzed with FACSCalibur and CellQuest software. 
 
Virus production 
 Cells lysate after Ad infection was examined for the cytotoxicity with A549 cells and the 
virus titers were calculated with the median tissue culture infectious dose (TCID50) method. 
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Results 
Cytotoxic activities of ZOL and Ad-delE1B55 on mesothelioma 
   We investigated possible combinatory cytotoxic effects produced by ZOL and Ad-delE1B55 
on 5 kinds of mesothelioma, MSTO-211H, NCI-H226, NCI-H28, EHMES-10 and NCI-H2452 
cells, which are defective of the p14ARF and p16INK4A genes but possess the wild-type p53 (Figure 
1). Cells treated with ZOL or Ad-delE1B55 showed decreased viability. A combinatory use of 
both ZOL and Ad-delE1B55 achieved cytotoxicity greater than a single treatment with either 
ZOL or Ad-delE1B55 (Figure 2A). CalcuSyn software analyses showed that CI values were 
below 1 in MSTO-211H, NCI-H226 and NCI-H28 cells at most of the Fa points tested, 
indicating that the combination of ZOL and Ad-delE1B55 achieved synergistic cytotoxicity. We 
also calculated live cell numbers of combination-treated cells (Figure 2B). Cell growth was 
gradually retarded, and the cell numbers reduced stronger in the combination than those treated 
with ZOL or Ad-delE1B55. Replication-incompetent Ad-LacZ minimally suppressed the 
proliferation. These data indicated that ZOL and Ad-delE1B55 induced growth arrest and 
produced synergistic cytotoxic effects on mesothelioma. 
 
Cell cycle changes induced by ZOL and Ad- delE1B55 
 We examined cell cycle changes with flow cytometry in MSTO-211H and NCI-H28 cells 
(Figure 3; Table 1 and 2). Ad-delE1B55 treatments increased hyperploid fractions, more than 
4N populations, and sub-G1 fractions and ZOL increased sub-G1 fractions in MSTO-211H cells 
(Figure 3A). A combinatory used further increased sub-G1 populations in comparison with 
treatments with of Ad-delE1B55 or ZOL alone. Induction of hyperploidy was greater in 
NCI-H28 cells than in MSTO-211H cells when they were infected with Ad-delE1B55, and ZOL 
minimally augmented S-phase populations in NCI-H28 cells (Figure 3B). Combination of both 
agents in NCI-H28 cells induced the same cell cycle changes that were produced by 
Ad-delE1B55 treatments. In contrast to MSTO-211H cells, combination treatment did not 
induce Sub-G1 but increased S-phase fractions probably because Ad-delE1B55–infected cells 
with hyperploid fractions did not enter into G2/M-phase but still stayed in G2-phase. Cells 
uninfected or infected with Ad-LacZ however showed a minimal level of polyploidy and 
Sub-G1 fractions did not increase markedly. 
 
Molecular changes induced by combination of ZOL and Ad-delE1B55 
 We examined a possible mechanism of combination effects produced by ZOL and 
Ad-delE1B55 with western blot analyses (Figure 4). We firstly detected viral gene E1A 
expression in MSTO-211H cells (Figure 4A). E1A became detectable at 24 hours after infection 
of Ad-delE1B55, but the levels were minimally different compared with the combination 
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treatment. We then examined expression levels of apoptosis-linked proteins (Figure 4B). 
MSTO-211H cells treated with both ZOL and Ad-delE1B55 showed up-regulated p53 
expression, p53 phosphorylation, and subsequently enhanced cleavage of caspase-3, 8, 9 and 
PARP at a greater level than those treated with ZOL or Ad-delE1B alone. We noticed that Bid 
expression was down-regulated after 96 hours, but truncated Bid, which contributes to the 
linkage between the death receptor- and the mitochondria-mediated apoptosis, was not induced. 
Interestingly, phosphorylation of H2AX, a marker of DNA damages, was augmented suggesting 
that DNA damages were involved in Ad-delE1B55-mediated cell death and the combination 
augmented the damages.  
 We also examined a possible involvement of autophagy pathways (Figure 4A). Beclin-1 or 
Atg5 expression did not show any enhancement and there was no transition from LC3A/B I to 
LC3A/B II accompanied by the combination. These data indicated that cell death induced by 
ZOL and Ad-delE1B was irrelevant to autophagy. 
 
Expression of Ad receptors and Ad infectivity with mesothelioma cells. 
 We examined expression level changes of CAR and integrin αvβ3 or αvβ5 molecules 
induced by ZOL treatment on 2 kinds of mesothelioma cells (Figure 5A). The expression levels 
expressed as mean fluorescent intensity were calculated as a percentage of untreated cells and 
ZOL did not influence the CAR (MSTO-211H; 108.2 ± 0.09, NCI-H28 cells; 100.63 ± 0.39) or 
αvβ3 (MSTO-211H; 100.7 ± 0.04, NCI-H28 cells; 97.9 ± 0.37) expression levels. In contrast, 
ZOL differentially affect the integrin αvβ5 expression levels (MSTO-211H; 115.9 ± 0.64, 
NCI-H28 cells (69.7 ± 0.2). We then tested Ad infectivity on mesothelioma using 
GFP-expressing Ad with flow cytometry (Figure 5B). The fluorescence intensity on NCI-H28 
cells was influenced by ZOL, but not on MSTO-211H cells. These results suggested that the Ad 
infectivity of Ad-delE1B55 was stronger in the combination than that without ZOL treatment 
although the expression levels of Ad receptors did not change.  
 
The effects of ZOL on viral proliferations of Ad-delE1B55.  
 We examined whether the enhanced combinatory effects were associated with increased 
production of the viral progenies by ZOL treatment. MSTO-211H and NCI-H28 cells were 
treated with ZOL and Ad-delE1B55, then the cell lysate was tested for the viral titers with the 
TCID50 method with A549 cells (Figure 6). There was no change in 211H cell, but ZOL 
treatment significantly suppressed viral propagation of Ad-delE1B55. The enhanced cell death 
by the combination was not thereby due to increased production of infectious Ad progenies on 
MSTO-211H cells, but could be linked with a new mechanism by ZOL that could influence 
Ad-delE1B55 replication on mesothelioma.  
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Discussion 
 In this study, we firstly examined that ZOL and Ad-delE1B55 induced growth arrest and 
produced synergistic cytotoxic effects on p53 wild-type mesothelioma. Sub-G1 populations 
increased compared with a single treatment of ZOL or Ad-delE1B55 in MSTO-211H cells. 
However, the combination in NCI-H28 cells did not induce Sub-G1 but increased S-phase 
populations. The mechanism of S-phase arrest induced by the combinatory treatment remain 
uncharacterized. The combinatory treatment induced p53 phosphorylation and subsequently 
enhanced the cleavage of caspase-3, 8, 9 and PARP, but did not influence expression of 
molecules implicated in autophagy pathways. H2AX was also phosphorylated, which suggested 
that a cellular system detecting viral DNA increase during the replications was activated. 
Hyperploidy could be due to a direct or an indirect consequence of accumulated viral DNA and 
an activated DNA damage sensor thereby phosphorylated H2AX molecules. However, it is 
currently unknown as for a precise mechanism of the combinatory effects on mesothelioma. 
 The majority of human mesothelioma possesses the wild type p53 gene but lacks the 
p14ARF and the 16INK4A genes, which subsequently disorganized the p53 and the pRb pathways, 
respectively. ZOL activated p53 pathways on mesothelioma even though the cell death did not 
depend on the p53 pathways in our recent study [10]. On the other hand, Ad-delE1B55 that 
produced cytotoxicity on mesothelioma induced in p53 phosphorylation, pRb 
dephosphorylation, and cleavage of caspases [16]. The present study indicated that combination 
phosphorylated p53 and up-regulated the expression levels, suggesting a crucial role of p53 
induction in the combination-mediated cytotoxicity.  
 The ZOL-induced cytotoxicity can be attributable to inhibited prenylation of small G 
proteins and showed a possible involvement of the p53 pathways in ZOL-mediated cytotoxicity 
[5, 8,9]. Ras and RhoA pathways were activated on malignant mesothelioma and 
extracellular-regulated kinase 1/2, p38 mitogen-activated protein kinase, and c-Jun N-terminal 
kinase were found to be active in most of the mesothelioma cell lines tested [11, 17]. Cell death 
caused by Ad-delE1B55 was associated with activated p53 pathways [18]. The combinatory 
effects were therefore associated with a possible cross-talk between small G proteins and the 
p53 pathways on mesothelioma. 
 We examined expression of Ad receptors and the Ad infectivity on mesothelioma cells. 
CAR and integrin αvβ3 expression levels on MSTO-211H and NCI-H28 cells were minimally 
different in ZOL-treated cells. Intriguingly, integrin αvβ5 expression was augmented in 
MSTO-211H and down-regulated in NCI-H28 cells after ZOL treatments although contribution 
of the differential expression to the Ad infectivity were unknown. By contrast, Ad replication of 
Ad-delE1B55 was stronger in the combination than that in ZOL treatment on NCI-H28 cells. 
These results suggested a possible mechanism connected with sub-G1 increase and S-phase 
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arrest which induced by the combinatory treatment. Ad replication processes are not directly 
associated with hyperploidy, but that differential cell death mechanisms, which are influenced 
by a number of genetic differences in infected cells, may also play a role in the aberrant cell 
cycle progression [19]. On the other hand, some studies showed that cells infected with 
Ad-delE1B55 during the G1 phase of cell cycle exhibited a reduced rate of viral late protein 
synthesis, produced fewer viral progeny, and were less efficiently killed than cells infected 
during the S-phase [20, 21]. Therefore, S-phase arrest which induced on NCI-H28 cells could 
enhance viral progeny 
 We also hypothesized a possible mechanism involved in the combinatory effects with small 
G proteins interactions between ZOL and Ad. Ad endocytosis via integrins requires activation of 
the lipid kinase phosphatidylinositol-3-OH kinase, which in turn augments signaling cascades of 
both Ras and Rho families [22]. In addition, our previous study showed that RhoA, Cdc42 and 
Rab6 were achievable targets for ZOL-induced actions [23]. These reports suggested that 
combinatory cytotoxicity of ZOL and Ad-delE1B55 was linked with small G proteins functions, 
however, precise interactions remained unknown. Our studies demonstrated synergistic 
anti-tumor effects induced by combination of ZOL and Ad-delE1B55 through multiple 
mechanisms. 
 
Conclusions 
 In this study, we examined ZOL and Ad-delE1B55 induced growth arrest and produced 
synergistic cytotoxic effects on p53 wild-type mesothelioma. We showed that the combination 
of ZOL and Ad-delE1B55 induced synergistic anti-tumor effects through apoptotic pathways. 
The interrelationship of small G proteins and the p53 pathways also play a role associated with 
the cell death on mesothelioma. 
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Abbreviations 
Ab: antibody; Ad: adenoviruses; Ad-delE1B55: Ad lacking the E1B-55kDa molecules; BPs: 
Bisphosphonates; CAR: coxsackie adenovirus receptor; CI: combination index; Fa: fractions 
affected; GFP: green fluorescent protein; H2AX: H2A histone family member X; LacZ: 
ß-galactosidase; MOI: multiplicity of infection; PARP: poly (ADP-ribose) polymerase; PI3K: 
lipid kinase phosphatidylinositol-3-OH kinase; pfu: plaque-forming unit; small G proteins: mall 
guanine-nucleotide-binding regulatory proteins; TCID50: median tissue culture infectious dose; 
vp: virus particles; ZOL: zoledronic acid. 
 10 
References 
1. Favoni RE, Florio T. Combined chemotherapy with cytotoxic and targeted compounds 
for the management of human malignant pleural mesothelioma. Trends Pharmacol Sci. 
2011;32:463-79. 
2. Carbone M, Kratzke RA, Testa JR. The pathogenesis of mesothelioma. Semin Oncol. 
2002; 29:2-17. 
3. Hopkins-Donaldson S, Belyanskaya LL, Simões-Wüst AP, Sigrist B, Kurtz S, 
Zangemeister-Wittke U, et al. p53-induced apoptosis occurs in the absence of p14(ARF) in 
malignant pleural mesothelioma. Neoplasia. 2006;8:551-9. 
4. Lee AY, Raz DJ, He B, Jablons DM. Update on the molecular biology of malignant 
mesothelioma. Cancer. 2007;109:1454-61. 
5. Yuasa T, Kimura S, Ashihara E, Habuchi T, Maekawa T. Zoledronic acid: a multiplicity 
of anti-cancer action. Curr Med Chem. 2007;14:2126-35. 
6. Lee MV, Fong EM, Singer FR, Guenette RS. Bisphosphonate treatment inhibits the 
growth of prostate cancer cells. Cancer Res. 2001;61:2602-8. 
7. Senaratne SG, Pirianov G, Mansi JL, Arnett TR, Colston KW. Bisphosphonates induce 
apoptosis in human breast cancer cell lines. Br J Cancer. 2000;82:1459-68. 
8. Green JR. Antitumor effects of bisphosphonates. Cancer. 2003;97:840-7. 
9. Green JR. Bisphosphonates: preclinical review. Oncologist. 2004;9:3-13. 
10. Jones RM., Morgan C, Bertelli G. Effects of zoledronic acid and docetaxel on small 
GTP-binding proteins in prostate cancer. Tumor Biol. 2015;36:4861-9. 
11. Okamoto S, Kawamura K, Li Q, Yamanaka M, Yang S, Fukamachi T, et al. Zoledronic 
acid produces antitumor effects on mesothelioma through apoptosis and S-phase arrest in 
p53-independent and Ras prenylation-independent manners. J Thorac Oncol. 2012;7:873-82. 
12. Okamoto S, Jiang Y, Kawamura K, Shingyoji M, Fukamachi T, Tada Y, et al. Zoledronic 
acid produces combinatory anti-tumor effects with Cisplatin on mesothelioma by increasing 
p53 expression levels. PLoS One. 2013;8(3): e60297. 
13. Yang CT, You L, Uematsu K, Yeh CC, McCormick F, Jablons DM. p14(ARF) modulates 
the cytolytic effect of ONYX-015 in mesothelioma cells with wild-type p53. Cancer Res. 
2001;61:5959-63. 
14. Bischoff JR, Kirn DH, Williams A, Heise C, Horn S, Muna M, et al. An adenovirus 
mutant that replicates selectively in p53-deficient human tumor cells. Science. 
1996;274:373-376.  
15. Soria C, Estermann FE, Espantman KC, O’Shea CC. Heterochromatin silencing of p53 
target genes by a small viral protein. Nature. 2010;466:1076-81. 
 11 
16. Yamanaka M, Tada Y, Kawamura K, Li Q, Okamoto S, Chai K, et al. E1B-55 
kDa-defective adenoviruses activate p53 in mesothelioma and enhance cytotoxicity of 
anticancer agents. J Thorac Oncol. 2012;7:1850-7. 
17. Patel MR, Jacobson BA, De A, Frizelle SP, Janne P, Thumma SC, et al. Ras pathway 
activation in malignant mesothelioma. J Thorac Oncol. 2007;2:789-95. 
18. Bar-Sagi D, Hall A. Ras and Rho GTPases: a family reunion. Cell. 2000;103:227-38. 
19. Yang S, Kawamura K, Okamoto S, Yamauchi S, Shingyoji M, Sekine I, et al. Cytotoxic 
effects of replication-competent adenoviruses on human esophageal carcinoma are enhanced 
by forced p53 expression. BMC Cancer. 2015;15:464. 
20. Goodrum FD, Ornelles DA. Roles for the E4 orf6, orf3, and E1B 55-kilodalton proteins 
in cell cycle-independent adenovirus replication. J Virol. 1999;73:7474-88. 
21. Goodrum FD, Ornelles DA. The early region 1B 55-kilodalton oncoprotein of 
adenovirus relieves growth restrictions imposed on viral replication by the cell cycle. J Virol. 
1997;71:548-61. 
22. Li E, Stupack D, Bokoch GM, Nemerow GR. Adenovirus endocytosis requires actin 
cytoskeleton reorganization mediated by Rho family GTPases. J Virol. 1998;72:8806-12. 
23. Okamoto S, Jiang Y, Kawamura K, Shingyoji M, Tada Y, Sekine I, et al. Zoledronic acid 
induces apoptosis and S-phase arrest in mesothelioma through inhibiting Rab family proteins 
and topoisomerase II actions. Cell Death Dis. 2014; doi:10.1038, e1517. 
 
 12 
Table 1. Cell cycle progressions of MSTO-211H cells treated with ZOL and/ or 
Ad-delE1B55. 
Cells 
Time 
(hr) 
Treatment 
Cell cycle distribution (%±SE) 
Sub-G1 G1 S G2/M >4N 
MSTO-211H 24 (-) 2.04±0.04 58.80±0.20 18.17±0.24 20.67±0.31 0.81±0.06 
  Ad-LacZ 2.90±0.16 57.30±0.19 17.59±0.22 20.97±0.26 1.83±0.04 
  Ad-delE1B55 2.61±0.16 55.29±0.07 20.41±0.11 20.08±0.27 2.22±0.11 
  ZOL 2.47±0.05 57.47±0.10 18.34±0.27 20.70±0.22 1.62±0.09 
  
ZOL+ 
Ad-LacZ 
3.58±0.17 55.98±0.16 17.94±0.17 20.84±0.10 2.22±0.08 
  
ZOL+ 
Ad-delE1B55 
3.72±0.05a 53.99±0.11a 20.53±0.23a 19.42±0.35 3.00±0.09 
 48 (-) 1.73±0.07 76.54±0.12 8.20±0.03 12.59±0.08 1.18±0.04 
  Ad-LacZ 1.37±0.08 75.90±0.38 8.60±0.16 12.55±0.33 1.82±0.03 
  Ad-delE1B55 12.25±0.04 51.87±0.21 12.47±0.13 21.56±0.19 2.32±0.03 
  ZOL 3.82±0.08 76.77±0.43 6.70±0.09 11.31±0.33 1.60±0.01 
  
ZOL+ 
Ad-LacZ 
2.81±0.11 76.08±0.33 7.47±0.12 11.95±0.13 1.96±0.06 
  
ZOL+ 
Ad-delE1B55 
19.69±0.18a 47.47±0.19a 15.42±0.44a 15.23±0.35 2.69±0.16 
 72 (-) 0.96±0.02 87.55±0.01 3.77±0.13 7.26±0.19 0.59±0.05 
  Ad-LacZ 1.46±0.10 87.58±0.30 2.75±0.05 7.79±0.14 0.51±0.03 
  Ad-delE1B55 22.52±0.07 43.47±0.18 11.57±0.14 12.89±0.23 10.14±0.23 
  ZOL 11.19±0.08 76.77±0.28 3.45±0.08 7.93±0.20 0.81±0.12 
  
ZOL+ 
Ad-LacZ 
6.44±0.03 80.27±0.15 3.04±0.04 9.66±0.13 0.78±0.04 
  
ZOL+ 
Ad-delE1B55 
35.52±0.05a 24.06±0.30a 13.89±0.13a 11.83±0.21b 15.41±0.19 
 96 (-) 1.03±0.07 87.25±0.01 4.43±0.03 6.93±0.06 0.50±0.03 
  Ad-LacZ 1.16±0.06 87.36±0.28 3.34±0.17 7.65±0.11 0.68±0.04 
  Ad-delE1B55 12.14±0.27 53.92±0.29 11.93±0.06 13.21±0.27 9.32±0.31 
  ZOL 9.32±0.11 80.72±0.21 3.98±0.06 5.73±0.07 0.40±0.07 
  
ZOL+ 
Ad-LacZ 
8.93±0.17 78.40±0.17 4.22±0.14 7.92±0.13 0.79±0.04 
  ZOL+ 40.75±0.08a 21.50±0.21a 14.26±0.11 10.58±0.12 13.59±0.18b 
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Ad-delE1B55 
Cells were treated with ZOL or Ad-delE1B55 (4.5x103 vp/cell) and compared with no treated or 
Ad-LacZ ( 4.5x103 vp/cell) and cultured for 24-96 hours. 
Cell cycle profiles were analyzed with flow cytometry. Mean percentages with SEs are shown 
(n=3). 
a p < 0.01, b p < 0.05; compared between ZOL+Ad-delE1B55-treated cells, and Ad-LacZ, ZOL-, 
Ad-delE1B55-, ZOL+Ad-LacZ-treated cells. 
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Table 2. Cell cycle progressions of NCI-H28 cells treated with ZOL and/ or 
Ad-delE1B55. 
Cells 
Time 
(hr) 
Treatmenta 
Cell cycle distribution (%±SE)b 
Sub-G1 G1 S G2/M >4N 
NCI-H28 24 (-) 8.57±0.34 57.61±1.07 15.48±0.53 16.96±0.89 0.92±0.21 
  Ad-LacZ 0.17±0.02 58.59±0.71 18.33±0.19 22.24±0.39 1.18±0.17 
  Ad-delE1B55 0.25±0.10 59.35±0.68 20.28±0.08 15.33±0.38 5.45±0.19 
  ZOL 0.16±0.03 61.76±0.64 25.71±0.31 212.15±0.48 0.89±0.05 
  
ZOL+ 
Ad-LacZ 
0.15±0.03 67.62±0.48 21.85±0.35 9.87±0.20 0.96±0.07 
  
ZOL+ 
Ad-delE1B55 
0.23±0.03 65.45±0.73a 17.33±0.21a 14.21±0.38a 3.24±0.24a 
 48 (-) 2.79±0.15 7.58±0.13 9.30±0.05 13.66±0.20 0.93±0.06 
  Ad-LacZ 0.24±0.01 73.42±0.15 9.22±0.21 16.30±0.20 1.08±0.13 
  Ad-delE1B55 1.17±0.05 1.70±0.22 8.77±0.22 36.84±0.12 51.80±0.28 
  ZOL 0.86±0.10 58.00±0.54 25.64±0.15 15.28±0.27 0.82±0.11 
  
ZOL+ 
Ad-LacZ 
0.70±0.03 60.80±0.20 25.40±0.27 12.92±0.28 0.77±0.03c 
  
ZOL+ 
Ad-delE1B55 
1.44±0.22a 19.93±1.20 47.98±1.01a 1.28±0.32a 0.64±0.37a 
 72 (-) 1.06±0.02 76.33±0.64 9.26±0.23 12.68±0.28 0.92±0.21 
  Ad-LacZ 0.51±0.06 76.20±0.37 8.68±0.26 13.50±0.46 1.41±0.07 
  Ad-delE1B55 6.67±0.17 2.15±0.23 5.12±0.49 27.45±0.26 59.21±0.85 
  ZOL 5.67±0.23 59.46±0.21 19.55±0.57 14.86±0.47 1.02±0.07 
  
ZOL+ 
Ad-LacZ 
6.07±0.13 61.94±0.30 16.93±0.16 14.56±0.12 0.97±0.11 
  
ZOL+ 
Ad-delE1B55 
8.56±0.38a 7.77±0.84a 41.33±1.20a 22.49±0.42 20.77±0.11a 
Cells were treated with ZOL or Ad-delE1B55 (4.5x103 vp/cell) and compared with no treated 
or Ad-LacZ (4.5x103 vp/cell) and cultured for 24-96 hours. 
Cell cycle profiles were analyzed with flow cytometry. Mean percentages with SEs are shown 
(n=3). 
a p < 0.01; compared between ZOL+Ad-delE1B55-treated cells, and Ad-LacZ, ZOL-, 
Ad-delE1B55-, ZOL+Ad-LacZ-treated cells. 
 15 
Figure legends 
Figure 1 Cytotoxic activities of ZOL or Ad-delE1B55 in mesothelioma. 
(A) Cells were treated with ZOL for 5 days and the cell viabilities were measured with the WST 
assay. The relative viabilities were calculated based on the absorbance without any treatments. 
Means of triplicated samples and SE bars are shown (n = 3). (B) Cells were infected with 
various amounts of Ad-delE1B55 and the viability was tested with the WST assay 5 days after 
the infection. Relative viability was calculated based on uninfected cells. Averages and SE bars 
are shown (n = 3).  
 
Figure 2 Combinatory effects produced by ZOL and Ad-delE1B55. 
(A) Cells were treated with different doses of ZOL and Ad-delE1B55 for 5 days and the cell 
viabilities were measured with the WST assay. Means of triplicated samples and the SE bars are 
shown (n=3). CI values based on the cell viabilities were determined by different Fa points with 
CalcuSyn software. (B) Cell proliferation were determined with the trypan blue dye exclusion 
test. SEs are shown. *p < 0.01, compared ZOL plus Ad-delE1B55-treated group with Ad-LacZ, 
ZOL-, Ad-delE1B55-, ZOL plus Ad-LacZ-treated cells group.  
 
Figure 3 Representative profiles of cell-cycle analyses.  
MSTO-211H (A) or NCI-H28 cells (B) were treated with ZOL and Ad-delE1B55 or Ad-LacZ 
(MSTO-211H: 4.5×103 vp/cell; NCI-H226: 1×103 vp/cell), and the cell cycles were analyzed 
with flow cytometry. 
 
Figure 4 Expression of molecules linked with cell death by combinatory treatment. 
MSTO-211H cells were treated with ZOL and Ad-delE1B55 or Ad-LacZ (3×103 vp/cell) as a 
control. Cells were cultured for the indicated times. Expression of viral proteins and autophagy 
pathways (A) and molecules linked with cell death pathways (B) were examined with western 
blot analyses. 
 
Figure 5 Expressions of Ad receptors and infectivity of Ad. 
(A) Expression of CAR and integrin αvβ3 or αvβ5 molecules in MSTO-211H and NCI-H28 
cells analyzed with flow cytometry. Representative profiles of cells untreated or treated with 
ZOL are shown. The thin line shows the mean fluorescent intensity of unstain cells and 
the thick line shows the mean fluorescent intensity of stain cells. (B) ZOL-mediated 
infection efficacy examined with Ad-GFP. Cells were infected at different MOI of Ad and mean 
fluorescent intensity of the GFP-positive cells are indicated. Averages and the SE bars are 
shown (n = 3).  
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Figure 6 Viral replications with the combination. 
Influence of ZOL on viral proliferation of Ad-delE1B55. MSTO-211H and NCI-H28 cells were 
treated with Ad-delE1B55 or in combination of ZOL (MSTO-211H: Ad-delE1B55 3×103 
vp/cell, ZOL 10 µM; NCI-H28: Ad-delE1B55 1×103 vp/cell, ZOL 50 µM) and the cell lysate 
was extracted at the indicated times. The viral titers were assayed with the TCID50 method. 
Means and SE bars are shown (n = 3).  
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